PL3204771T3 - Sposoby i systemy rozróżniania zespołu jelita drażliwego od nieswoistego zapalenia jelit i celiakii - Google Patents

Sposoby i systemy rozróżniania zespołu jelita drażliwego od nieswoistego zapalenia jelit i celiakii

Info

Publication number
PL3204771T3
PL3204771T3 PL15849701.6T PL15849701T PL3204771T3 PL 3204771 T3 PL3204771 T3 PL 3204771T3 PL 15849701 T PL15849701 T PL 15849701T PL 3204771 T3 PL3204771 T3 PL 3204771T3
Authority
PL
Poland
Prior art keywords
disease
systems
methods
inflammatory bowel
bowel syndrome
Prior art date
Application number
PL15849701.6T
Other languages
English (en)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars-Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars-Sinai Medical Center filed Critical Cedars-Sinai Medical Center
Publication of PL3204771T3 publication Critical patent/PL3204771T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15849701.6T 2014-10-09 2015-10-08 Sposoby i systemy rozróżniania zespołu jelita drażliwego od nieswoistego zapalenia jelit i celiakii PL3204771T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061877P 2014-10-09 2014-10-09
US201462085825P 2014-12-01 2014-12-01
PCT/US2015/054655 WO2016057772A1 (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Publications (1)

Publication Number Publication Date
PL3204771T3 true PL3204771T3 (pl) 2025-07-28

Family

ID=55653760

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15849701.6T PL3204771T3 (pl) 2014-10-09 2015-10-08 Sposoby i systemy rozróżniania zespołu jelita drażliwego od nieswoistego zapalenia jelit i celiakii

Country Status (16)

Country Link
US (2) US10132814B2 (pl)
EP (1) EP3204771B1 (pl)
JP (1) JP6784669B2 (pl)
KR (1) KR102426541B1 (pl)
CN (1) CN107003308B (pl)
AU (1) AU2015330872B2 (pl)
CA (1) CA2962493C (pl)
ES (1) ES3028294T3 (pl)
IL (1) IL251606B (pl)
MX (1) MX384921B (pl)
NZ (1) NZ730490A (pl)
PL (1) PL3204771T3 (pl)
PT (1) PT3204771T (pl)
RU (1) RU2706361C2 (pl)
SG (1) SG11201702395WA (pl)
WO (1) WO2016057772A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
AU2013315981B2 (en) 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
CN113447649B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2003097854A2 (en) 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
EP2444409A2 (en) 2002-09-16 2012-04-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2280285A1 (en) 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
PT1698698E (pt) 2003-12-05 2014-03-06 Fuso Pharmaceutical Ind Genes da toxina distensora citoletal como alvos para a deteção de bactérias campylobacter
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
PL2223121T3 (pl) 2007-12-20 2012-12-31 Index Diagnostics Ab Publ Sposób różnicowania NZJ i ZJD oraz dalsze rozróżnienie odmian NZJ
WO2010045180A1 (en) 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
AU2010213708B2 (en) 2009-02-11 2015-12-10 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
JP5477671B2 (ja) 2012-02-28 2014-04-23 三菱マテリアル株式会社 サーミスタ用金属窒化物材料及びその製造方法並びにフィルム型サーミスタセンサ
AU2013315981B2 (en) * 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
PE20160882A1 (es) 2013-10-09 2016-09-14 Cedars Sinai Medical Center Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
KR102426541B1 (ko) 2014-10-09 2022-07-29 세다르스-신나이 메디칼 센터 과민성 장 증후군을, 염증성 장 질환 및 셀리악 병과 구별하기 위한 방법 및 시스템
KR20190111094A (ko) 2017-01-30 2019-10-01 세다르스-신나이 메디칼 센터 경피증의 진단

Also Published As

Publication number Publication date
EP3204771A4 (en) 2018-03-14
SG11201702395WA (en) 2017-04-27
AU2015330872A1 (en) 2017-04-13
RU2017115663A3 (pl) 2019-05-16
JP2017531801A (ja) 2017-10-26
WO2016057772A1 (en) 2016-04-14
CN107003308A (zh) 2017-08-01
ES3028294T3 (en) 2025-06-18
AU2015330872B2 (en) 2021-04-22
US20190187153A1 (en) 2019-06-20
US10132814B2 (en) 2018-11-20
CN107003308B (zh) 2020-02-11
RU2017115663A (ru) 2018-11-13
EP3204771B1 (en) 2025-03-12
KR20170067795A (ko) 2017-06-16
US10690679B2 (en) 2020-06-23
JP6784669B2 (ja) 2020-11-11
CA2962493A1 (en) 2016-04-14
MX384921B (es) 2025-03-14
NZ730490A (en) 2021-07-30
US20160103136A1 (en) 2016-04-14
EP3204771A1 (en) 2017-08-16
IL251606A0 (en) 2017-06-29
IL251606B (en) 2020-08-31
PT3204771T (pt) 2025-05-20
MX2017004516A (es) 2017-10-12
RU2706361C2 (ru) 2019-11-18
KR102426541B1 (ko) 2022-07-29
CA2962493C (en) 2023-01-10

Similar Documents

Publication Publication Date Title
IL257857A (en) Blood clot retrieval system
SG11201701855RA (en) Systems and methods for liveness analysis
SG11201606716VA (en) Video analysis system
GB201517055D0 (en) An acoustic detection system
GB2525011B (en) Cooking system
GB2533284B (en) Performing object detection
IL251606A0 (en) Methods and systems for diagnosing irritable bowel syndrome from inflammatory bowel disease and celiac disease
GB201408100D0 (en) Detection method
GB201409766D0 (en) Signal processing methods
GB201402644D0 (en) Methylation detection method
GB201418499D0 (en) Malware detection method
ZA201607571B (en) Compositions and methods for detecting huanglongbing
IL259904A (en) Multiple threat detection system
GB201504373D0 (en) Computer system testing
GB201416459D0 (en) Detection method
GB201409182D0 (en) Capacitive detection system
GB201419330D0 (en) Detection method
SG11201610262TA (en) Object detection system
SG11201508484QA (en) Charging processing system
GB201903180D0 (en) Fire detection device
SG10201406350UA (en) An event detection method
GB201707731D0 (en) Detection system
GB201418707D0 (en) Flue system
GB201402174D0 (en) Detection method
GB2532935B (en) Proximity detection system